- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Voclosporin.
Displaying page 1 of 1.
| EudraCT Number: 2020-001467-82 | Sponsor Protocol Number: P020.051 | Start Date*: 2020-10-23 | ||||||||||||||||
| Sponsor Name:Leiden University Medical Center | ||||||||||||||||||
| Full Title: An Open-Label Study Evaluating Anti-Viral Effects of Voclosporin in SARS-CoV-2 Positive Kidney Transplant Recipients – the VOCOVID Study (COVID-19) | ||||||||||||||||||
| Medical condition: SARS-CoV-2 infection in Kidney Transplant Recipients | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: NL (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2020-005807-37 | Sponsor Protocol Number: AUR-VCS-2020-03 | Start Date*: 2022-04-08 | |||||||||||
| Sponsor Name:Aurinia Pharmaceuticals Inc. | |||||||||||||
| Full Title: A Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Efficacy, Safety and Pharmacokinetics of Voclosporin in Adolescents with Lupus Nephritis | |||||||||||||
| Medical condition: Lupus Nephritis | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) FR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-022128-63 | Sponsor Protocol Number: LX211-11 | Start Date*: 2011-03-16 |
| Sponsor Name:Lux Biosciences, Inc. | ||
| Full Title: A Multi-center, Double-Masked, Parallel Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Voclosporin as Therapy in Subjects with Active Non-Infectious Uveitis Involving the Inte... | ||
| Medical condition: Non-Infectious Intermediate, Posterior or Pan-uveitis | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) AT (Completed) IT (Completed) GB (Completed) NL (Ongoing) CZ (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-004045-81 | Sponsor Protocol Number: AUR-VCS-2016-01 | Start Date*: 2017-05-16 | |||||||||||
| Sponsor Name:Aurinia Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Achieving Renal Response in Subjects with Active Lupus Ne... | |||||||||||||
| Medical condition: Lupus Nephritis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BG (Completed) ES (Completed) NL (Completed) PL (Completed) HR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-003364-51 | Sponsor Protocol Number: AUR-VCS-2012-01 | Start Date*: 2014-10-24 | |||||||||||
| Sponsor Name:Aurinia Pharmaceuticals Inc. | |||||||||||||
| Full Title: A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) with Placebo in Achieving Remission in Patients with Active Lupus Nephritis | |||||||||||||
| Medical condition: Active lupus nephritis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) BG (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-004046-28 | Sponsor Protocol Number: AUR-VCS-2016-02 | Start Date*: 2018-05-23 | |||||||||||
| Sponsor Name:Aurinia Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A Randomized, Controlled, Double-blind, Continuation Study Comparing the Long-term Safety and Efficacy of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Subjects with Lupus Nephritis | |||||||||||||
| Medical condition: Lupus Nephritis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) BG (Completed) HR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-005528-12 | Sponsor Protocol Number: VIB7734.P2.S1 | Start Date*: 2021-08-17 | |||||||||||
| Sponsor Name:Viela Bio, Inc. | |||||||||||||
| Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus | |||||||||||||
| Medical condition: Systemic Lupus Erythematosus (SLE) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.